SLC5A2 and hydrops fetalis: Overall, an RR of 0.69 (0.59–0.81, P < 0.00001) corresponding to a relative risk reduction of 31% in favour of SGLT2 inhibitors was found for HHF [the requirement of intravenous medications such as cardiotonics, diuretics and vasodilators to treat worsening HF] Figure 3(c).